BNP Paribas Financial Markets
VRCA icon

BNP Paribas Financial Markets’s Verrica Pharmaceuticals VRCA Stock Holding History

BNP Paribas Financial Markets’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$582 Hold
110
– – ﹤0.01% 5529
2025
Q4 		$914 Sell
110
-14
-11% -$78 ﹤0.01% 5413
2025
Q3 		$534 Sell
124
-14
-10% -$84 ﹤0.01% 5307
2025
Q2 		$731 Sell
138
-138
-50% -$743 ﹤0.01% 5184
2025
Q1 		$1.22K Buy
276
+8
+3% +$52 ﹤0.01% 5041
2024
Q4 		$1.87K Sell
268
-157
-37% -$1.73K ﹤0.01% 5021
2024
Q3 		$6.17K Buy
425
+263
+162% +$11.8K ﹤0.01% 3829
2024
Q2 		$11.8K Sell
162
-872
-84% -$67K ﹤0.01% 3708
2024
Q1 		$61.2K Sell
1,034
-2,965
-74% -$164K ﹤0.01% 3549
2023
Q4 		$293K Buy
3,999
+2,713
+211% +$111K ﹤0.01% 3075
2023
Q3 		$50K Buy
1,286
+675
+110% +$34.3K ﹤0.01% 3468
2023
Q2 		$35.3K Buy
611
+549
+885% +$33.3K ﹤0.01% 3537
2023
Q1 		$4.06K Sell
62
-76
-55% -$4.6K ﹤0.01% 3598
2022
Q4 		$3.81K Buy
138
+87
+171% +$2.32K ﹤0.01% 3687
2022
Q3 		$1.49K Sell
51
-1,217
-96% -$41.7K ﹤0.01% 4379
2022
Q2 		$24.3K Buy
1,268
+1,148
+957% +$57.7K ﹤0.01% 3679
2022
Q1 		$9.74K Sell
120
-329
-73% -$27.1K ﹤0.01% 3805
2021
Q4 		$41.1K Buy
449
+191
+74% +$21.6K ﹤0.01% 3771
2021
Q3 		$32.2K Buy
258
+195
+310% +$21.9K ﹤0.01% 3601
2021
Q2 		$7.15K Sell
63
-114
-64% -$13.8K ﹤0.01% 3781
2021
Q1 		$26.8K Sell
177
-106
-37% -$14.7K ﹤0.01% 3717
2020
Q4 		$32.5K Sell
283
-47
-14% -$4.32K ﹤0.01% 3727
2020
Q3 		$25.5K Buy
330
+258
+358% +$21.1K ﹤0.01% 3749
2020
Q2 		$7.88K Sell
72
-330
-82% -$38.2K ﹤0.01% 3809
2020
Q1 		$43.9K Buy
402
+141
+54% +$18.6K ﹤0.01% 3607
2019
Q4 		$41.4K Buy
261
+75
+40% +$11.1K ﹤0.01% 3738
2019
Q3 		$27.4K Buy
186
+28
+18% +$3.12K ﹤0.01% 3807
2019
Q2 		$18.4K Sell
158
-68
-30% -$6.38K ﹤0.01% 3925
2019
Q1 		$24.4K Buy
+226
New +$26.1K ﹤0.01% 3847
2018
Q4 		– Hold
0
– – – 4282

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Financial Markets's VRCA Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Verrica Pharmaceuticals (VRCA) position steady in Q1 2026 at 110 shares worth $582. The position accounts for ﹤0.01% of the portfolio, ranked #5529.

BNP Paribas Financial Markets first reported a position in VRCA in Q1 2019 and has held it in 29 quarters since. The position peaked at $293K in Q4 2023. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • BNP Paribas Financial Markets held 110 shares of Verrica Pharmaceuticals worth $582 as of Q1 2026.
  • BNP Paribas Financial Markets left its Verrica Pharmaceuticals share count unchanged in Q1 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5529 holding.
  • BNP Paribas Financial Markets first reported a position in Verrica Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Verrica Pharmaceuticals position peaked at $293K in Q4 2023.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.